Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials.

Cancers (Basel) · 2022 · PMC9026788 · PMID 35454826

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

HR-NBL1 study patients (R2 and R4 combined) who were not in complete remission (non-CR) before immunotherapy showed a trend towards a higher incidence of severe neurotoxicity (patients with severe neurotoxicity: 86% non-CR vs. 15% CR, patients without neurotoxicity: 55% non-CR vs. 45% CR; p = 0.0628; Fishers exact test).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.